Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nvidia Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223 (market cap $29.60B), while Nvidia Corp trades at $223.92 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 178× Alnylam Pharmaceuticals, Inc.'s market cap, and Nvidia Corp pays a 0.46% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NVDA | |
|---|---|---|
Market Cap | $29.60B | $5.27T |
Sector | Health | Technology |
52-Week High | $491.22 | $235.75 |
52-Week Low | $205.48 | $165.17 |
Enterprise Value | $27.56B | $5.20T |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
NVIDIA (NVDA) trades at $217.48, down 0.04% on the day, with a bullish technical signal and strong fundamentals. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.87 exceeding the $1.76 estimate. Revenue surged to $130.50 billion in 2025, driving a net income margin of 62.97%. The stock faces overbought signals with RSI at 77.70, but support levels near $216 provide a cushion.
Outlook remains positive due to AI chip dominance and robust growth projections, though risks include competition and market volatility. Analysts project a $325.86 price target with 75% buy ratings, highlighting long-term potential amid high valuations like a P/E of 33.31.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
